Business
Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, ...
About this update from Aspire Biopharma Holdings, Inc.
[{"type":"text","content":"HUMACAO, PR AND NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, CEO of Aspire, will present at the Emerging Growth Conference.","length":333,"tagName":"p"},{"type":"text","content":"Virtual Presentation DetailsDate: April 17, 2025Time of Presentation: 12:35 p.m. EDTFormat: Corporate presentation with Q&A","length":130,"tagName":"p"},{"type":"text","content":"Participants can register for and view the webcast, along with accompanying slides, here: https://goto.webcasts.com/starthere.jsp?ei=1705403&tp_key=612b99c876&sti=asbp","length":175,"tagName":"p"},{"type":"text","content":"If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.","length":241,"tagName":"p"},{"type":"text","content":"This event follows the recently announced initiation of its Phase 1 single-center clinical study of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation. This Phase 1 trial is expected to provide information required to select the optimal drug product formulation and inform the design of a second clinical trial, if needed, to support FDA approval. Following completion of this trial, Aspire plans to request a pre-IND meeting with the FDA in the second quarter of 2025 to finalize plans for continued development of high-dose aspirin leading to submission of a section 505(b)(2) NDA seeking approval to market the product for treatment of suspected acute myocardial infarction.","length":721,"tagName":"p"},{"type":"text","content":"About the Aspire Targeted Oral Delivery Platform","length":48,"tagName":"p"},{"type":"text","content":"Aspire's technology delivers a soluble, fast acting granular or powder form drug formulation which has been developed by using our patent-pending methodology, and "trade secret" process. The technologies new mechanism of action allows for rapid sublingual absorption and entry into the bloodstream. The benefits of "rapid absorption" are to provide nearly instant tr...